Skip to content
Acceleron Pharma

Investors/Media

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Apr 26, 2017
- Management to review highlights from luspatercept clinical presentations at the 14th International MDS Symposium - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commerci...
Apr 6, 2017
Oral presentation highlights new Phase 2 data in additional sub-populations of lower-risk MDS CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative...
Mar 16, 2017
- Second Phase 2 study for ACE-083 expected to begin 2H 2017 - - Company to host educational webinar with leading clinical researcher on April 3rd at 11:00 a.m. EDT - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical ...
Mar 1, 2017
- Luspatercept Phase 3 trials to complete enrollment in both the MDS ("MEDALIST") and beta-thalassemia ("BELIEVE") trials in 2H 2017 - - Presented data from five abstracts on luspatercept and sotatercept at the American Society of Hematology Annual Meeting in December - - Treated f...
Feb 28, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Feb 22, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the Company will host a live conference call and webca...
Feb 1, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming ...
Jan 6, 2017
- Luspatercept MEDALIST Phase 3 trial in MDS expected to complete enrollment in the 2nd half of 2017 - - Luspatercept BELIEVE Phase 3 trial in beta-thalassemia expected to complete enrollment in the 2nd half of 2017 - - Plan to initiate new luspatercept Phase 2 clinical trials in ...
Jan 4, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that Habib Dable, President and Chief Executive Officer, wil...
Dec 22, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the first patient has been treated in a Phase 2 clinic...
Dec 5, 2016
- Interim longer term data with investigational drug luspatercept show sustained increases in hemoglobin levels, and reduced transfusion burden in patients with beta-thalassemia - CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN) and Celg...
Dec 5, 2016
- Preliminary results show that treatment with investigational drug sotatercept can increase hemoglobin and achieve transfusion independence in patients with myelofibrosis - - Acceleron to host conference call and live webcast on Monday, December 5th at 9:00 a.m. EST (6:00 a.m. PST) - ...
Dec 4, 2016
- Preliminary results show that treatment with investigational drug luspatercept increases hemoglobin and achieves durable transfusion independence in patients with lower risk myelodysplastic syndromes - - Preliminary data in ESA naïve and RS- patients are encouraging - - Acce...
Nov 30, 2016
- Management to review highlights from luspatercept and sotatercept clinical presentations - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative t...
Nov 3, 2016
- Appointed Habib Dable as President and CEO effective December 1, 2016 - - Five upcoming presentations at American Society of Hematology Annual Meeting in December - - Advancing ACE-083 into Phase 2 study for facioscapulohumeral muscular dystrophy (FSHD) - ...
Nov 3, 2016
- Oral and poster presentations span multiple hematologic diseases including myelodysplastic syndromes, beta-thalassemia and myelofibrosis - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, developme...
Nov 2, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will present at the 25th Annual Cred...
Oct 27, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the Company will host a live conference call and webcas...
Oct 13, 2016
Webcast to be held October 28, 2016 at 10:00 a.m. EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases,...
Sep 27, 2016
- Habib Dable Appointed as President and CEO - - Leadership Transition Highlights Acceleron's Progression to its Next Stage of Growth - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the ...
Aug 31, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming ...
Aug 4, 2016
- Presented positive data that confirms and extends longer term Phase 2 safety and efficacy results for luspatercept in myelodysplastic syndromes and beta-thalassemia - - Presented positive Phase 1 ACE-083 results showing increases in muscle volume in the tibialis anterior muscle in healthy volunt...
Jul 28, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that the Company will host a ...
Jul 25, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced the appointment of the experi...
Jul 8, 2016
-ACE-083 increased muscle volume of the tibialis anterior muscle by 8.9% in healthy volunteers- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidate...
Jun 29, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that results from the Phase 1...
Jun 10, 2016
- Preliminary results show that treatment with investigational drug luspatercept results in clinically meaningful increases in hemoglobin and durable transfusion independence in patients with lower risk myelodysplastic syndromes - - Acceleron to host conference call and live webcast today at 8:00 ...
Jun 10, 2016
- Longer term data with investigational drug luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden, and improved patient reported quality of life measures in patients with beta-thalassemia - - Acceleron to host conference call and live webcast today...
Jun 7, 2016
Management to review highlights from presentations of ongoing Phase 2 clinical trials in MDS and beta-thalassemia CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic ...
Jun 1, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that senior management will ...
May 19, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that data from four abstracts...
May 5, 2016
- Received $15 million milestone payment for Celgene's initiation of luspatercept Phase 3 clinical trial - - Raised $140.3 million in net proceeds to advance wholly owned programs - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical s...
Apr 28, 2016
Conference Call and Webcast to be Held on Thursday, May 5, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebui...
Apr 26, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today announced that senior management will ...
Mar 1, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that senior management will participate in four ...
Feb 25, 2016
- Initiated Phase 3 trials with luspatercept in MDS and beta-thalassemia with partner Celgene - - Received Fast Track Designation for luspatercept in MDS and beta-thalassemia, and for dalantercept in RCC - - Presented initial Phase 1 results for ACE-083, a locally acting t...
Feb 18, 2016
Conference Call and Webcast on February 25, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and r...
Feb 1, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that senior management will participate in two u...
Jan 5, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that it has priced an underwritten public offeri...
Jan 4, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that it intends to offer and sell, subject to ma...
Dec 7, 2015
Luspatercept increased hemoglobin levels, reduced transfusion burden, improved health-related quality of life measures and had beneficial effects on liver iron concentration in patients with beta-thalassemia SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG)...
Dec 7, 2015
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of anemia in patients with lower-risk myelodys...
Dec 5, 2015
Luspatercept increased hemoglobin levels and generated transfusion independence in patients with lower risk myelodysplastic syndromes SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced preliminary resul...
Dec 1, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, announced that a late breaking abstract describing results from ...
Nov 24, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced it will present a corporate overview at the Pip...
Nov 5, 2015
- Presentations span multiple hematologic diseases including myelodysplastic syndromes, beta-thalassemia, multiple myeloma and myelofibrosis - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused ...
Nov 4, 2015
- ACE-083 Phase 1 results demonstrate an unprecedented increase in muscle volume. Phase 2 clinical trials planned to start next year - - ACE-2494 generates significant increases in muscle mass in preclinical studies. Phase 1 clinical trial of ACE-2494 planned to start next year - ...
Nov 2, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced it will participate in the following upcoming in...
Oct 29, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that the Company will host a conference call and...
Oct 23, 2015
- Phase 3 Studies in Myelodysplastic Syndromes ("MEDALIST") and Beta-thalassemia ("BELIEVE") Outlined - - ACE-083 Preliminary Phase 1 Results Demonstrate 14% Increase in Muscle Volume - - Acceleron Unveils IntelliTrap™ Platform to Design New Class of Highly Selective...
Oct 15, 2015
- Presentations Will Highlight Luspatercept Phase 3 Trial Designs, ACE-083 Phase 1 Trial Results, and the First Clinical Candidate from Acceleron's New IntelliTrapTM Discovery Platform - - Presentations to be given by members of Acceleron and Celgene management and external clinical exper...
Oct 2, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported that its collaboration partner, Celgene, and ...
Oct 1, 2015
-- First presentation of data for new systemic muscle agent, ACE-2494, demonstrates substantial increases in muscle mass -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercia...
Sep 2, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced it will participate in the following upcoming in...
Aug 6, 2015
- Completed luspatercept myelodysplastic syndromes phase 2 clinical trial - - FDA Fast Track Designations granted to luspatercept for the treatment of patients with beta-thalassemia - - Phase 3 clinical trials with luspatercept in lower risk myelodysplastic syndromes and b...
Jul 29, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that the Company will host a conference call and...
Jun 15, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that new study findings involving the use of dalantercept to b...
Jun 12, 2015
- In lower risk myelodysplastic syndromes patients, longer-term treatment with luspatercept led to sustained increases in hemoglobin levels and transfusion independence - - In both transfusion and non-transfusion dependent beta-thalassemia patients, luspatercept demonstrated durable increases in h...
Jun 9, 2015
- Highlights from two oral presentations on MDS and beta-thalassemia clinical trials - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic...
May 27, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced it will participate in the following upcoming in...
May 21, 2015
- Two oral presentations of phase 2 clinical trials in beta-thalassemia and lower-risk myelodysplastic syndromes - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization o...
May 18, 2015
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designations to luspatercept for two separate indications; the use of luspatercept for the t...
May 13, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that data from the DART study, an ongoing phase ...
May 7, 2015
- Luspatercept phase 2 data showed encouraging activity in lower risk myelodysplastic syndromes (MDS) patients - - Celgene and Acceleron selected luspatercept to advance into Phase 3 programs in MDS and beta-thalassemia by year-end - - Promising data from dalantercept phase 2 clini...
May 2, 2015
- In lower risk myelodysplastic syndromes patients, luspatercept increased hemoglobin levels and enabled transfused patients to become transfusion independent - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focuse...
Apr 30, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that Acceleron and its collaboration partner, Ce...
Apr 28, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that the Company will host a conference call and...
Apr 23, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced it will participate in the following upcoming in...
Apr 7, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that abstracts for the luspatercept and sotaterc...
Apr 6, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced the appointment of Francois Nader, M.D., M.B.A, ...
Mar 6, 2015
- Steven Ertel named Executive Vice President and Chief Operating Officer - - Matthew Sherman, M.D. named Executive Vice President and Chief Medical Officer - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical ...
Mar 2, 2015
- Phase 2 data from luspatercept trials in β-thalassemia and MDS patients given as oral presentations at ASH and MDS abstract included in "Best of ASH" session - - Plans with Celgene to initiate phase 3 clinical trials in both β-thalassemia and MDS in 2015 - - So...
Feb 28, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported new preliminary data from the DART study, an ongo...
Feb 26, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced it will participate in the following upcoming in...
Feb 24, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that the company will host a conference call and...
Feb 19, 2015
-- Preliminary Data from Part 1 of the Phase 2 DART Renal Cell Carcinoma Trial Selected for Oral Presentation -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and comme...
Jan 28, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in the following upcoming investor confere...
Jan 12, 2015
- Phase 3 Clinical Trials in both MDS and Beta-Thalassemia Planned for 2015 - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and...
Dec 15, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it has been selected for addition to the NASDAQ Biotechnology Index® (N...
Dec 12, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Francois Nader, M.D., M.B.A, to its Board of Directors. ...
Dec 10, 2014
Luspatercept Presentation Chosen Among More Than 4,000 Abstracts CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare d...
Dec 8, 2014
Luspatercept and sotatercept increased hemoglobin levels and achieved transfusion independence in patients with lower risk myelodysplastic syndromes SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today ann...
Dec 7, 2014
Luspatercept increased hemoglobin levels, reduced transfusion burden and improved measures of iron overload in beta-thalassemia patients SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the presenta...
Nov 24, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in several upcoming investor conferences. ...
Nov 13, 2014
Sotatercept slowed progression of vascular calcification and improved abnormal changes in bone mineral density Sotatercept produced dose dependent increases in hemoglobin CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutic...
Nov 7, 2014
- Phase 2 data from beta-thalassemia and MDS trials selected for oral presentations at ASH - - Phase 2 data from end-stage renal disease trial to be presented at ASN - - Initiated final stage of beta-thalassemia and MDS phase 2 clinical trials - - ...
Nov 6, 2014
Phase 2 data from beta-thalassemia trial selected for oral presentation Phase 2 data from myelodysplastic syndromes trial selected for oral presentation CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical ...
Oct 30, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the company will host a conference call and live audio w...
Oct 29, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will participate in several upcoming investor conferences. ...
Oct 23, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that its collaboration partner, Celgene, and investigators on ...
Oct 22, 2014
Prominent nephrologist, Ravi Thadhani, M.D., M.P.H. to lead third seminar in Acceleron series CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel prot...
Oct 14, 2014
-- Locally administered investigational therapeutic designed to increase muscle mass in treated muscles -- -- Fourth internally discovered drug expands Acceleron's clinical pipeline -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinica...
Oct 1, 2014
-- Prominent hematology expert, Ellis Neufeld, M.D., Ph.D. will lead online seminar -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein the...
Sep 29, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will present a corporate overview at the Leerink Partners R...
Sep 23, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced results from an interim report for a two-part clinical study s...
Sep 16, 2014
First in the series will be myelodysplastic syndromes (MDS) with Professor Uwe Platzbecker, M.D. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel p...
Aug 27, 2014
Cambridge, Mass. - August 27, 2014 - Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that over the next two weeks, it will participate in several investor conferences....
Aug 12, 2014
-- Encouraging interim data presented from five phase 2 clinical trials -- -- Two additional phase 2 studies initiated -- -- Pipeline advancement and expansion demonstrate potential value of late-stage clinical opportunities -- CAMBRIDGE, Mass.--(BUSI...
Aug 5, 2014
Conference Call and Webcast on August 12, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare dis...
Jul 14, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Terrence C. Kearney to its Board of Directors and to the ...
Jun 19, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the JMP Securities Healthcare Conference ...
Jun 14, 2014
SUMMIT, NJ and CAMBRIDGE, MASS – (June 14, 2014) – Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced interim data from two studies of candidates from the companies' joint development program in beta-thalassemia. The data presented at the 19th European Hematology Association (EHA) annual congress ...
May 29, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that over the next three weeks, it will provide corporate pres...
May 21, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today reported that Acceleron, Celgene and investigators in the sotatercept an...
May 15, 2014
Positive clinical data from all three phase 2 programs to be presented at ASCO and EHA meetings Follow-on offering solidifies financial position and provides funding into second half of 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (N...
May 14, 2014
Study advancing to randomized, placebo-controlled stage of the clinical trial CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics...
May 12, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the 2014 UBS Global Healthcare Conference...
May 8, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the company will host a conference call and live audio we...
Apr 23, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, presented...
Mar 24, 2014
Two papers in the journal Nature Medicine describe role of TGF-beta superfamily signaling in red blood cell formation and the ability of sotatercept and ACE-536 to promote late-stage erythropoiesis through an EPO-independent mechanism SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...
Mar 20, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the 21st Annual Future Leaders in the ...
Mar 17, 2014
Sotatercept produces dose dependent increases in hemoglobin with no dose dependent changes in blood pressure CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Feb 27, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the Cowen and Company 34th Annual Health ...
Feb 26, 2014
Strong financial position and positive clinical data from several phase 2 clinical trialsInitiation of a phase 3 clinical trial in beta-thalassemia expected by the end of 2014 or early 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceu...
Feb 19, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the company will host a conference call and live audio we...
Feb 5, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the 2014 Leerink Global Healthcare Confer...
Jan 28, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the closing of its underwritten public offering of 2,760,000 s...
Jan 22, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the pricing of a public offering of 2,400,000 shares of common...
Jan 21, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that it has commenced an underwritten public offering of $100 ...
Jan 9, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that it has filed a registration statement on Form S-1 with th...
Dec 20, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, has been selected for addition to the Russell 2000®, Russell 3000® ...
Dec 18, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene, has initiated a phase...
Dec 9, 2013
Dose-dependent increases in hemoglobin demonstrated in non-transfusion dependent patientsIncreases in hemoglobin of at least 1-2 g/dL observed in most patients at 0.3 and 0.5 mg/kg dose levelsSignificant relationship between hemoglobin increase and drug exposure across dose ranges tested ...
Dec 3, 2013
Plans to initiate phase 2 study of dalantercept plus sorafenib in hepatocellular cancer in the first half of 2014 Remains on track to initiate pivotal trial with sotatercept or ACE-536 in late 2014 or early 2015 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma In...
Dec 2, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in five abstracts for sotatercept and ACE-536, Accel...
Nov 25, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the Piper Jaffray 25th Annual Healthcare ...
Nov 6, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today provided a corporate update and reported financial results for the third...
Nov 5, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma, Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron ...
Oct 30, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma, Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the company will host a conference call and live audio w...
Sep 24, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma, Inc. (NASDAQ:XLRN) today announced the closing of its initial public offering of 6,417,000 shares of common stock, including 837,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares to co...
Sep 18, 2013
CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Acceleron Pharma, Inc. today announced the pricing of...
Aug 7, 2013
Cambridge, Mass. – August 7, 2013 – Acceleron Pharma, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price ...
Jun 4, 2013
Click here to view article Cambridge, Mass. – June 4, 2013 –...
May 10, 2013
Cambridge, Mass. – May 10, 2013 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, today announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito Bastianello Award for best abstract and oral pr...
May 2, 2013
Cambridge, Mass. – May 2, 2013 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today reported that Shire plc (LSE: SHP, NASDAQ: SHPG) has concluded the collaboration with Acceleron on ACE-031 and related molecules.  The clinical development of ACE-031...
Mar 26, 2013
Cambridge, Mass. – March 26, 2013 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that the United States Food and Drug Administration (FDA) granted orphan designation for ACE-536 for the treatment of beta-thalassemia and for the t...
Mar 7, 2013
Cambridge, Mass. – March 7, 2013 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic di...
Feb 5, 2013
Cambridge, Mass. – February 5, 2013 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.  The phase ...
Feb 5, 2013
Cambridge, Mass. – February 5, 2013 –Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or p...
Jan 29, 2013
Cambridge, Mass. – January 29, 2013 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).&nbs...
Jan 28, 2013
Link to abstract
Jan 3, 2013
Cambridge, Mass. – January 3, 2013 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the 31st Annual J.P. Morgan Healthcare Conf...
Nov 14, 2012
Cambridge, Mass. – November 14, 2012 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with recurrent or persistent endometrial cancer.&...
Nov 7, 2012
Link to abstract
Nov 5, 2012
Link to article
Oct 25, 2012
Cambridge, Mass. – October 25, 2012 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented data today at the 3rd Pan-European Conference on Hemoglobinopathies and Rare Anemias in Limassol, Cyprus, demonstrating positive effects of ACE-536 to t...
Oct 11, 2012
Cambridge, Mass. – October 11, 2012 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and its collaborators are presenting data at the 2012 Markers in Cancer Conference in Hollywood, Fla., a joint meeting sponsored by ASCO, EORTC, and the NCI, that...
Sep 27, 2012
Click here for a link to the article - Acceleron one of only two biopharmaceutical companies to make the list -...
Sep 12, 2012
Cambridge, Mass. – September 12, 2012 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced that Tom Maniatis, Ph.D., an Acceleron co-founder and Professor and Chair of the Department of Biochemistry and Molecular Biophysics at the Columbia U...
Jul 3, 2012
Link to abstract
Apr 3, 2012
Cambridge, Mass. – April 3, 2012 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced that collaborators at Beth Israel Deaconess Medical Center presented preclinical data today at the American Association for Cancer Researc...
Dec 23, 2011
CAMBRIDGE, Mass. – December 23, 2011 –  Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private financing.  Celgene, one of Acceleron’s strategic partners, and all other existing investors participat...
Nov 28, 2011
CAMBRIDGE, Mass. – November 28, 2011 –  Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it will give corporate presentations at two upcoming investor conferences.  John Knopf, Ph.D., Chief Executive Officer, will provide a...
Sep 13, 2011
CAMBRIDGE, Mass. – September 13, 2011 –  Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536.  ACE-536 is a ligand trap that increases red blood cells and hemoglobin by ...
Sep 12, 2011
CAMBRIDGE, Mass. – September 12, 2011 –  Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that John Knopf, Ph.D., Chief Executive Officer, will provide a corporate presentation at the Rodman & Renshaw Annual Global Investmen...
Aug 5, 2011
August 5, 2011
Aug 4, 2011
August 4, 2011
Aug 3, 2011
Scrip Intelligence: Celgene Pays Acceleron $25M Upfront Under Anemia Drug Partnership
Aug 3, 2011
SUMMIT, NJ and CAMBRIDGE, Mass. – August 3, 2011 –  Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation (NASDAQ: CELG) today announced that the companies have entered into a joint development and commercialization agreement...
Jun 30, 2011
ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011; 117(26): 6999-7006
Jun 2, 2011
SUMMIT, NJ and CAMBRIDGE, Mass.– June 2, 2011 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, and Celgene Corporation (NASDAQ: CELG) today announced the initiation of the first part of a Phase 2/3 clinical study of ACE-011 (sotatercept) for the t...
May 9, 2011
Cambridge, Mass. – May 9, 2011 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.  Treatment with the investigational compou...
May 1, 2011
Link to abstract
Apr 5, 2011
ORLANDO, Florida – April 5, 2011 – Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today presented positive results from a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) path...
Mar 30, 2011
CAMBRIDGE, Mass – March 30, 2011 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced that Steven Ertel, Senior Vice President Corporate Dev...
Mar 1, 2011
Link to abstract
Dec 1, 2010
Link to abstract
Nov 29, 2010
CAMBRIDGE, Mass – November 29, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced that Kevin F. McLaughlin has joined Acceleron as Se...
Nov 19, 2010
CAMBRIDGE, Mass – November 19, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-...
Nov 19, 2010
Cambridge, Mass.– November 19, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced that Jasbir Seehra, Ph.D., Co-Founder and Chief Scientific Officer of ...
Nov 2, 2010
Cambridge, Mass. – November 2, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded grants for five projects under the Qualifying Th...
Oct 13, 2010
Cambridge, Mass. – October 13, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tole...
Oct 1, 2010
Link to abstract
Sep 15, 2010
Cambridge, Mass.- September 15, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced that it has been selected by the editors of FierceBiotech as one of ...
Sep 9, 2010
Cambridge, Mass. – September 9, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical com...
Sep 1, 2010
A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health. Endocrinology 2010; 151(9): 4289–4300
Aug 19, 2010
CAMBRIDGE, Mass.– August 19, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-0...
Aug 4, 2010
CAMBRIDGE, Mass.– August 4, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular ...
Jul 2, 2010
Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB. J Biol Chem 2010; 285(27): 21037–21048
May 13, 2010
Administration of a Soluble Activin Type IIB Receptor Promotes Skeletal Muscle Growth Independent of Fiber Type. J Appl Physiol 2010;109(3):635-42
May 5, 2010
CAMBRIDGE, Mass. – May 5, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular D...
Apr 1, 2010
Link to abstract
Mar 23, 2010
CAMBRIDGE, Mass. – March 23, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrati...
Mar 16, 2010
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. PNAS 2010, 107(11): 5124-5129
Mar 10, 2010
CAMBRIDGE, Mass. – March 10, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat and the vasculature, today announced that it was recognized by VentureSource, a unit of Wall Street Journal owner News Corp. a...
Mar 1, 2010
CAMBRIDGE, Mass. – March 1, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat and the vasculature, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron will provide a corporate pres...
Feb 2, 2010
ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. Mol Cancer Ther 2010; 9(2): 379–88
Jan 14, 2010
San Francisco, Calif. – January 14, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced that it has expanded its development pipeline to seven molecules with the advancement o...
Jan 7, 2010
CAMBRIDGE, Mass. – January 7, 2010 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate ...
Jan 1, 2010
Link to abstract
Jan 1, 2010
Link to abstract
Dec 22, 2009
CAMBRIDGE, Mass. – December 22, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the expansion of its management team with two newly created key positions. The Compan...
Dec 8, 2009
CAMBRIDGE, Mass. – December 8, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of ...
Dec 3, 2009
CAMBRIDGE, Mass., Dec 03, 2009 – Alkermes, Inc. (NASDAQ: ALKS) and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptide...
Dec 1, 2009
CAMBRIDGE, Mass. – December 1, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents,...
Nov 4, 2009
CAMBRIDGE, Mass. – November 4, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor ...
Nov 1, 2009
The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond). 2009; 33(11): 1265-1273
Oct 28, 2009
Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction. Am J Physiol Regul Integr Comp Physiol 298: R96–R103, 2010
Sep 15, 2009
CAMBRIDGE, Mass. – September 15, 2009 –Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle and the vasculature today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron will provide a corporate presen...
Sep 10, 2009
CAMBRIDGE, Mass. – September 10, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial demonstrating tha...
Jul 30, 2009
CAMBRIDGE, Mass. – July 30, 2009 –Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone and muscle, today announced that Steven Ertel, Vice President Corporate Development of Acceleron will provide a corporate ...
Jul 28, 2009
CAMBRIDGE, Mass. – July 28, 2009 –Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone and muscle, and Celgene Corporation (NASDAQ: CELG) today announced the initiation of a second Phase 2 clinical study of AC...
Jun 10, 2009
CAMBRIDGE, Mass. – June 10, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced it will provide three oral presentations on data from its ACE-031 program at the Endocrine S...
Jun 8, 2009
CAMBRIDGE, Mass.- June 8, 2009 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced it will provide presentations at two upcoming investor conferences, at the following locations and ti...
May 1, 2009
CAMBRIDGE, Mass. – May 1, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle, red blood cells, and vasculature, today announced that it has signed a lease on a third facility in Cambridge, further expanding it...
May 1, 2009
CAMBRIDGE, Mass. – May 1, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle, red blood cells, and vasculature, today announced that it has been selected as one of the 2009 Best Places to Work by the Boston Business Journal. The...
Apr 14, 2009
CAMBRIDGE, Mass. – April 14, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone, muscle, red blood cells and vasculature, today announced that it will present results from preclinical studies of its anti-angiogenesis program, A...
Mar 26, 2009
CAMBRIDGE, Mass.– March 26, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, today announced that Steven Ertel, Vice President, Corporate Development of Acceleron, will provide a corpora...
Mar 12, 2009
CAMBRIDGE, Mass. – March 12, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron will provide a corporate presen...
Feb 17, 2009
February 17, 2009
Jan 13, 2009
SAN FRANCISCO, Calif.– January 13, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, today announced that it has designated a new development candidate, ACE-536, which selectively increas...
Jan 6, 2009
CAMBRIDGE, Mass. – January 6, 2009 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentat...
Dec 18, 2008
CAMBRIDGE, Mass. and SUMMIT, NJ – December 18, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, today announced the publication of the ACE-011 Phase 1 clinical study demonstrating that A...
Dec 3, 2008
CAMBRIDGE, Mass. – December 3, 2008 – Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that results from preclinical and clinical studies of ACE-011 will be presented...
Dec 1, 2008
Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women. J Bone Min Res 2009;24:744–752
Nov 3, 2008
CAMBRIDGE, Mass. – November 3, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentati...
Oct 24, 2008
CAMBRIDGE, Mass. – October 24, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Steven Ertel, Vice President, Corporate Development of Acceleron, will provide a corporate presentation at the 7...
Oct 20, 2008
CAMBRIDGE, Mass. – October 20, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 1 clinical study of ACE-031, its lead compound for treating diseases involving the loss of mu...
Oct 16, 2008
CAMBRIDGE, Mass. – October 16, 2008 – Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the initiation of a Phase 2 clinical study of its lead compound ACE-011 in pati...
Sep 30, 2008
CAMBRIDGE, Mass.- September 30, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the Third Annual JMP ...
Sep 22, 2008
CAMBRIDGE, Mass. – September 22, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, announced that the company is a finalist in the Greater Boston region for the Fifth Annual Team Massachusetts Economic Impact Award...
Sep 19, 2008
CAMBRIDGE, Mass. – September 19, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the UBS...
Jun 20, 2008
CAMBRIDGE, Mass. – June 20, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the Jefferies 2nd...
Jun 16, 2008
CAMBRIDGE, Mass. – June 16, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that as part of its rapid growth and expansion it is increasing headcount by nearly 40% and doubling the size of its adm...
Jun 4, 2008
CAMBRIDGE, Mass. – June 4, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Steven Ertel, Vice President Corporate Development of Acceleron, will provide a corporate presentation at the Needha...
May 13, 2008
CAMBRIDGE, Mass. – May 13, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Steven Ertel, Vice President Corporate Development of Acceleron, will provide a corporate presentation at the Rodman...
May 13, 2008
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008; 105(19): 7082-7087
May 7, 2008
CAMBRIDGE, Mass. – May 7, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced the publication of key preclinical data from its ACE-011 program demonstrating that treatment using the ActRIIA receptor i...
Mar 24, 2008
CAMBRIDGE, Mass. – March 24, 2008 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it has received the upfront payment from Celgene Corporation following clearance under the Hart-Scott-Rodino Antitrust Improv...
Mar 11, 2008
CAMBRIDGE, Mass. – March 11, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron will provide a corporate presentation at the Cowen and Com...
Feb 25, 2008
BioCentury Feb 25, 2008
Feb 21, 2008
BioWorld Today, Feb 21, 2008
Feb 20, 2008
CAMBRIDGE, Mass. & SUMMIT, N.J.– Feb. 20, 2008 – Acceleron Pharma, Inc. and Celgene Corporation today announced a worldwide strategic collaboration for the joint development and commercialization of ACE-011, a first-in-class, novel bone-forming compound. The collaboration combines both companies’ resources and commitment to...
Jan 23, 2008
Cambridge, Mass. – January 23, 2008 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that it was selected to receive a Biotech Investment Award from the Multiple Myeloma Research Foundation to support the...
Nov 20, 2007
Cambridge, Mass. – November 20, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer at Acceleron, will provide a corporate presentation at the Lazard Capital Ma...
Nov 1, 2007
Cambridge, Mass. – November 1, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that it will provide a corporate presentation at the Massachusetts Biotechnology Council’s (MBC) 9th Annual MASS ...
Oct 31, 2007
BioWorld Today, October 31, 2007
Oct 31, 2007
Cambridge, Mass. – October 31, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the Acumen Bio...
Oct 30, 2007
Cambridge, Mass. – October 30, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it raised $31M in a Series C financing. Bessemer Venture Partners led the round along with other new investors MPM BioE...
Oct 18, 2007
Link to article
Oct 18, 2007
Cambridge, Mass. – October 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced results of a preclinical study with ACE-031, the company’s lead product for the treatment of muscular dystrophy, ...
Oct 4, 2007
Cambridge, Mass. – October 4, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, announced that the Web Marketing Association (“WMA”) awarded a “Pharmaceutical Industry Standard of Excellence”...
Oct 2, 2007
Cambridge, Mass. – October 2, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the Natixis Bleic...
Sep 24, 2007
Cambridge, Mass. – September 24, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Niels Borgstein, M.D. has joined Acceleron as Vice President, Medical Research. Dr. Borgstein has more than 10...
Sep 20, 2007
Cambridge, Mass. – September 20, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the UBS 2007 Global ...
Sep 20, 2007
Cambridge, Mass. – September 20, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that ACE-011 improved bone microarchitecture, increased bone mineral density and bone mechanical strength. The result...
Sep 18, 2007
Honolulu, HI – September 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced positive results for the phase 1 clinical trial of ACE-011 at The American Society for Bone and Mineral Research (ASBMR) ...
Sep 18, 2007
Cambridge, MA – September 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John L. Knopf, Ph.D., has been named as the Chief Executive Officer of Acceleron. Dr. Knopf has also been elected t...
Aug 6, 2007
CAMBRIDGE, MA – August 6, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it will present the final results for the phase 1 clinical trial of ACE-011, its novel anabolic therapy for the treatment of...
Aug 1, 2007
Pharmaceutical Executive, August 1, 2007
Jul 31, 2007
CAMBRIDGE, MA – July 31, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel biotherapeutics, today announced that company President and Founder, John Knopf, Ph.D., will provide a corporate presentation at the 27th Annual Canaccord Adams Global Growth Conference on Tuesday August 7, 2007 at 1:30 pm ...
Jul 16, 2007
Link to article
Jun 26, 2007
Kos, Greece – June 26, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced results demonstrating that ACE-011, a novel anabolic bone agent for the treatment of bone loss, preserved bone mass and...
Jun 1, 2007
Start-Up: June 1, 2007
May 14, 2007
LUCCA, ITALY – May 14, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced results of a preclinical study with ACE-031 that demonstrated the ability of the compound to increase muscle mass and s...
Apr 25, 2007
CAMBRIDGE, MA – April 25, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced the appointment of James Desiderio, Ph.D. as Vice President, Program Management.. “The Acceleron pro...
Apr 1, 2007
Link to article
Mar 29, 2007
CAMBRIDGE, MA – March 29, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced the appointment of Robert Steininger as Senior Vice President, Manufacturing. “Acceleron is rapidly advancing and ...
Mar 7, 2007
CAMBRIDGE, MA – March 7, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel biotherapeutics, today announced that Steven Ertel, Vice President Business Development, will provide a corporate presentation at the Cowen and Company 27th Annual Health Care Conference on Thursday March 15, 2007 at 9:30...
Nov 3, 2006
CAMBRIDGE, MA – November 3, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company developing regenerative therapeutics, today announced that Glenn Batchelder, Chief Executive Officer, will provide a corporate presentation at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, 2006 at 4:55 p.m. (EST)....
Oct 30, 2006
CAMBRIDGE, MA – October 30, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, today announced that Glenn Batchelder, Chief Executive Officer, will provide a corporate presentation at the Massachusetts Biotechnology Council’s MASS Opportunities Conference on Thur...
Sep 18, 2006
CAMBRIDGE, MA – September 18, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, presented preclinical data highlighting the anabolic bone activity of ACE-011, the company’s lead drug candidate currently in a phase 1 clinical trial, at the Annual Meeting of the A...
Sep 12, 2006
CAMBRIDGE, MA – September 12, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, announced that it will present preclinical data highlighting the anabolic bone activity of ACE-011, the company’s lead drug candidate and a novel treatment for bone loss, at the Annu...
Aug 21, 2006
Red Herring, August 21, 2006
Aug 3, 2006
BioWorld Today, August 3, 2006
Aug 2, 2006
CAMBRIDGE, MA – August 2, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics, today announced that it secured a $30 million Series B financing. OrbiMed Advisors, the sole new investor, led the round with participation by all existing institutional investors including Ad...
Jul 17, 2006
BioCentury, July 17, 2006
Jun 21, 2006
CAMBRIDGE, MA – June 21, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company involved in the development of regenerative therapeutics , announced that it has initiated a Phase 1 clinical trial of ACE-011, a novel treatment for bone loss disease, particularly osteoporosis. ACE-011 is the first regenerative therapeutic to enter ...
May 16, 2006
CAMBRIDGE, MA – May 16, 2006 – Acceleron Pharma, Inc., a biopharmaceutical company focused on developing and commercializing therapeutics based on its novel tissue growth factor platform, today announced the appointment of Matthew L. Sherman, M.D. as Senior Vice President and Chief Medical Officer. “Acceleron has built ...
Jun 14, 2004
CAMBRIDGE, MA – June 14, 2004 – Acceleron Pharma announced today the appointment of Glenn Batchelder as president and CEO and a member of the board of directors. Batchelder has been a senior executive at Millennium Pharmaceuticals for the past five years. Acceleron also announced that biopharmaceutical veteran Richard Pops, CEO ...
Feb 13, 2004
BOSTON, MA – February 13, 2004 – Acceleron Pharma, a biopharmaceutical company developing drugs to treat musculoskeletal and metabolic disorders, announced today that it has raised $25 million in its first round of private equity financing. The company has an exceptional team and a set of proprietary approaches that will enable it to...
Page:
...
Next Last
 
= add release to Briefcase